Paradigm Biopharmaceuticals Ltd
PAR
Company Profile
Business description
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
Contact
500 Collins Street
Level 15
MelbourneVIC3000
AUST: +61 396295566
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
The shunned ASX player offering attractive value
Making the case for coal amidst a tough few years for investors
stocks
What did Morningstar subscribers buy and sell during November?
And what do our analysts think of the investments?
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,746.20 | 17.70 | 0.20% |
| CAC 40 | 7,303.28 | 47.86 | 0.66% |
| DAX 40 | 20,232.14 | 215.39 | 1.08% |
| Dow JONES (US) | 45,014.04 | 308.51 | 0.69% |
| FTSE 100 | 8,335.81 | 23.60 | -0.28% |
| HKSE | 19,742.46 | 3.86 | -0.02% |
| NASDAQ | 19,735.12 | 254.21 | 1.30% |
| Nikkei 225 | 39,610.43 | 334.04 | 0.85% |
| NZX 50 Index | 12,908.62 | 11.95 | 0.09% |
| S&P 500 | 6,086.49 | 36.61 | 0.61% |
| S&P/ASX 200 | 8,477.90 | 15.30 | 0.18% |
| SSE Composite Index | 3,364.65 | 14.16 | -0.42% |